ApoRx is a drug-discovery company focusing on the discovery, design, characterization, and development of small proteolysis-targeting molecules against well-validated disease-causing proteins in cancer and other indications. The core of its technology is the Aperion library, a proprietary focus library of RING E3 ligase binders that is designed to harness the intracellular ubiquitin-proteasome machinery to degrade and destroy unwanted proteins via targeted protein degradation. ApoRx is a subsidiary of Agbiopro Protein Degradation Hub, a management and consulting firm.